ALS Mouse Model Crossing Study
Objective: To evaluate the protective effects of Nrf2 activation in astrocytes on disease onset and survival in ALS mouse models by crossing GFAP-Nrf2 transgenic mice with two ALS-mouse models
Gather these items before starting the experiment. Check off items as you prepare.
Materials1
Not specified • Not specified • Not specified • Not specified
As an Amazon Associate, we earn from qualifying purchases. Product links help support this free resource.
Protocol Steps
Generate transgenic mice
Generated transgenic mice over-expressing Nrf2 selectively in astrocytes using the glial fibrillary acidic protein (GFAP) promoter
Note: GFAP promoter used for astrocyte-specific expression
View evidence from paper
“We generated transgenic mice over-expressing Nrf2 selectively in astrocytes using the glial fibrillary acidic protein (GFAP) promoter”
Cross GFAP-Nrf2 mice with ALS-mouse models
Crossed the GFAP-Nrf2 mice with two different ALS-mouse models to evaluate protective effects
Note: Two separate ALS-mouse models were used
View evidence from paper
“This protective effect was also observed by crossing the GFAP-Nrf2 mice with two ALS-mouse models”
Monitor disease onset
Monitored and recorded the onset of disease symptoms in crossed mice
Note: Nrf2 over-expression in astrocytes significantly delayed onset
View evidence from paper
“Over-expression of Nrf2 in astrocytes significantly delayed onset and extended survival”
Monitor survival
Tracked and recorded survival duration in crossed mice
Note: Nrf2 over-expression extended survival in ALS models
View evidence from paper
“Over-expression of Nrf2 in astrocytes significantly delayed onset and extended survival”